NCT06811532

Brief Summary

The gold standard for reconstruction of the jaw is the utilization of a bone free tissue transfer. Scapula reconstruction is an excellent option for elderly patients, those with significant comorbidities and for complex defects with large soft tissue reconstructive requirements. The scapula is supplied by the angular artery and circumflex scapula arteries. No studies have shown with objective measures, the viability of the lateral border of the scapula bone supplied by either the angular artery or circumflex scapula arteries. The aim of this observational study is to demonstrate with objective clinical measures, via SPY-Q software analysis, that the angular artery can adequately supply the scapula tip flap including with a single osteotomy giving two bone segments, in 30 patients who will undergo reconstructive head and neck surgery at LHSC.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for all trials

Timeline
10mo left

Started May 2025

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress58%
May 2025Mar 2027

First Submitted

Initial submission to the registry

January 31, 2025

Completed
6 days until next milestone

First Posted

Study publicly available on registry

February 6, 2025

Completed
3 months until next milestone

Study Start

First participant enrolled

May 7, 2025

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 28, 2027

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

March 30, 2027

Last Updated

April 9, 2025

Status Verified

April 1, 2025

Enrollment Period

1.8 years

First QC Date

January 31, 2025

Last Update Submit

April 8, 2025

Conditions

Keywords

head and neck cancerscapular free flapblood perfusion

Outcome Measures

Primary Outcomes (2)

  • Adequacy of blood perfusion of osteomized lateral border of the scapula bone supplied by the angular artery

    To measure the adequacy of blood perfusion of osteotomised lateral border of the scapula bone supplied by the angular artery via SPY-Q analysis in patients undergoing a scapular tip flap for reconstruction of a jaw defect

    Intra-operatively

  • Blood perfusion of osteomized lateral border of the scapula

    To measure the adequacy of blood perfusion of osteotomised lateral border of the scapula bone supplied by the angular artery via SPY-Q analysis in patients undergoing a scapular tip flap for reconstruction of a jaw defect

    Intra-operatively

Secondary Outcomes (3)

  • To assess flap viability

    Intra-operatively; up to 10 days post-operatively

  • Concordance between subjective and objective measure of blood perfusion

    Intra-operatively; up to 10 days post-operatively

  • Blood perfusion of latissmus dorsi

    Intra-operatively

Interventions

Use of the SPY-Q analysis software during surgery to calculate bone profusion scores on several areas of the scapular tip flap (endosteum of scapula bone segments and latissimus dorsi muscle component).

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with advanced head and neck cancer, benign tumors of the jaw and osteoradionecrosis, scheduled for head and neck reconstructive surgery using the scapular tip flap at London Health Sciences Centre (LHSC).

You may qualify if:

  • Adult patients (18 years and older) seen at the head and neck clinic at London Health Sciences Centre (LHSC)
  • Planned to undergo a maxillary and/or mandibular reconstruction surgery with a scapular tip flap

You may not qualify if:

  • Younger than 18 years of age
  • History of failing microvascular flaps
  • Hypersensitivity toward ICG or related substances (e.g., imaging agents), defined as (based on ICG product monograph): possibly life-threatening dizziness, severe itching, hives, nausea, difficulty breathing, rash, low blood pressure)
  • Pregnant
  • Breastfeeding
  • Clinically apparent cognitive impairment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Head and Neck Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasms

Study Officials

  • Danielle MacNeil, MD

    Department of Otolaryngology-Head & Neck Surgery, Western University Canada

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Agnieszka Dzioba, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

January 31, 2025

First Posted

February 6, 2025

Study Start

May 7, 2025

Primary Completion (Estimated)

February 28, 2027

Study Completion (Estimated)

March 30, 2027

Last Updated

April 9, 2025

Record last verified: 2025-04

Data Sharing

IPD Sharing
Will not share

Data will be made available upon request